REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New drug tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial is testing a new drug called tegavivint in patients with an aggressive type of lymphoma that has returned or stopped responding to other treatments. The main goals are to find a safe dose and understand the drug's side effects. Researchers hope the drug can…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC